만성 요통 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global chronic back pain market size is expected to reach USD 7.25 Billion in 2034 from USD 3.04 Billion in 2025, growing at a CAGR of 10.14% during 2026-2034.This market is expanding steadily due to the increasing prevalence of chronic back pain and the growing demand for effective treatment solutions. Chronic back pain is a common condition affecting individuals across all age groups, often resulting from lifestyle factors, injuries, and degenerative diseases. The rising aging population and the increasing incidence of sedentary lifestyles are key factors driving market growth. Additionally, the growing awareness of pain management options is contributing to increased adoption of treatment solutions.

Key drivers include advancements in medical technologies and the development of innovative therapies for pain management. Treatments such as minimally invasive surgeries, physical therapy, and pain relief medications are widely used. The increasing focus on improving patient quality of life is also supporting market growth. Furthermore, the expansion of healthcare infrastructure and access to treatment options in emerging regions are contributing to market expansion.

Future prospects of the chronic back pain market are promising, with continuous innovation expected in treatment approaches and technologies. Companies are likely to focus on developing personalized and non-invasive treatment solutions. The integration of digital health technologies and wearable devices will further enhance patient monitoring and management. As awareness and healthcare access continue to improve, the market is expected to grow steadily.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

• Non-steroidal Anti-Inflammatory Drugs
• Antidepressants
• Analgesic
• Opioids
• Others

By Route of Administration

• Oral
• Topical
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, Medtronic plc, Eli Lilly and Company, Merck & Co., Inc., Sanofi, GSK plc, Bayer AG, AbbVie Inc., Abbott Laboratories, Boston Scientific Corporation, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Dr. Reddy's Laboratories Ltd., Astellas Pharma Inc., Stryker Corporation, Zimmer Biomet Holdings Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC BACK PAIN MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Non-steroidal Anti-Inflammatory Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Analgesic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Opioids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC BACK PAIN MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC BACK PAIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC BACK PAIN MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHRONIC BACK PAIN INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Johnson & Johnson Services Inc
  • 9.2.2 Pfizer Inc
  • 9.2.3 Novartis AG
  • 9.2.4 Medtronic Plc
  • 9.2.5 Eli Lilly And Company
  • 9.2.6 Merck & Co.Inc
  • 9.2.7 Sanofi
  • 9.2.8 GSK Plc
  • 9.2.9 Bayer AG
  • 9.2.10 AbbVie Inc
  • 9.2.11 Abbott Laboratories
  • 9.2.12 Boston Scientific Corporation
  • 9.2.13 Teva Pharmaceutical Industries Ltd
  • 9.2.14 AstraZeneca Plc
  • 9.2.15 Dr. Reddy-(TM)s Laboratories Ltd
  • 9.2.16 Astellas Pharma Inc
  • 9.2.17 Stryker Corporation
  • 9.2.18 Zimmer Biomet Holdings Inc